Introduction of leptin into APP/PS1 mice using lentiviral gene therapy approaches results in an overall decrease in Aβ accumulation as well as recovery of some of the AD-related synaptic deficits [74,75]. The gene discussed is APP; the disease is Alzheimer disease.